ClinicalTrials.gg
TerminatedNCT02357472DHEAUpdated Jun 24, 2025Results posted

The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders

An interventional study of dehydroepiandrosterone in Infertility, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Terminated at 1 site in China. Open to female participants aged 22 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Health services research

How we know

Why this study was terminated
Many patients couldn't wait for DHEA treatment for three months.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2014, registered Jan 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
22 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing dehydroepiandrosterone in Infertility — 2 open to participants now, 2 under way, 1 of them phase 3. Dehydroepiandrosterone · Infertility.

Enrollment
9th of 13
60 · median 140
Started
2014
with 2 others
No phase
3 of 13
1 open now
Registered
6th of 13
by date
Lead sponsor
2 of 13
ShangHai Ji Ai Genetics & IVF Institute

Among the 13 studies testing dehydroepiandrosterone in Infertility, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 3 with no phase, and was the 6th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

2 of the 13 studies testing dehydroepiandrosterone in Infertility are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dehydroepiandrosterone

Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 22 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing dehydroepiandrosterone in Infertility, or all of them as a file.
02

Study summary

The supplementation of Dehydroepiandrosterone (DHEA) has been used in some centers for patients with previous poor ovarian reserve and response in an attempt to improve pregnancy outcomes. However, there still has controversy on the clinical effect on the 75mg/d for the use,especially in Asian people. Whether the double dosage of DHEA in patients with poor ovarian reserve and response in China can improve the IVF outcome with little side effect is unknown.

The aim of this randomized controlled study is to compare the effect of a higher dose (150mg daily) and a standard dose (75mg daily) of DHEA on the number of oocytes obtained in poor ovarian responders. The effect of DHEA action on the cumulus cells will be examined.

Read the detailed description

Consecutive infertile women attending the subfertility clinic at Shang Hai Ji Ai Genetics \&IVF Institute for IVF treatment will be approached. Those fulfilling the selection criteria stated below would be recruited and a written consent will be obtained after detailed explanation and counseling.

Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3 of the following:

(i) Advanced maternal age (>/= 40) or any other genetic or acquired risk factor for poor ovarian response(POR); (ii) Previous poor ovarian response (POR) (\</= 3 oocytes with a conventional stimulation protocol using at least 150 international units (IU) gonadotrophins per day) (iii) Abnormal ovarian reserve test [i.e. antral follicle count (AFC) \< 5-7 or antimüllerian hormone (AMH) \< 0.5 - 1.1ng/ml]

Alternatively, two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test(ORT).

Baseline assessment will be performed at early follicular phase (Day 2 or 3) at recruitment. Patient characteristics including age, Body Mass Index (BMI), and smoking status would be recorded and blood test including follicular stimulating hormone (FSH), estradiol (E2), testosterone, DHEA-S, full blood count, renal and liver function test would be checked. Pelvic scan will be performed to assess the total AFC and total ovarian volume.

Subjects will be randomized divided into two groups:

  1. Standard dose group: Subjects will take DHEA (Lab Hercules™) 25mg three times a day for 12 weeks prior to the start of IVF treatment till the day of egg collection.
  2. High dose group: Subjects will taking DHEA (Lab Hercules™) 50mg three times a day for 12 weeks prior to the start of IVF treatment till the day of egg collection.

Hormonal profile, ultrasound assessment, full blood count, renal and liver function test will be repeated in follicular phase (D2 or 3) of every month or cycle followed by a IVF treatment using antagonist protocol based on our standard departmental regimen. The human menopausal gonadotropin (hMG) injections were started at 300 international units (IU) for 2 days followed by 300 international units (IU) daily. Improvement of ovarian reserve markers would be assessed by the change in serum AMH between the time of recruitment and that after 6 and 12 weeks of DHEA. Cycle characteristics including the dose of gonadotrophins use, duration of stimulation, number of oocytes obtained, number of fertilized embryos and good quality embryos will be recorded and follicular fluid will be saved for hormonal profiles.

Statistics

  1. Statistical tests

    Statistical comparisons will be performed according to the intention to treat principle by Student t test or Fisher's exact tests for normally distributed data and Mann-Whitney test for skewed data. Chi-square test would be used for binary variables. Statistical analyses will be performed using the Statistical Package for (the) Social Sciences (SPSS) software and a P-value of 0.05 would be considered statistically significant. Linear regression analysis / logistic regression analysis curve would be used to evaluate the age, BMI, smoking, FSH, E2, AMH, testosterone, DHEA-S, AFC, ovarian volume and duration of DHEA use for the prediction of improved ovarian reserve after DHEA supplementation.

  2. Sample size estimation

The number of oocytes retrieved will be used as the primary outcome of the study. Based on our own database for patients undergoing IVF treatment, the mean oocytes obtained was 2.7 with a standard deviation (SD) of 1.4. Assuming an increase of oocytes obtained by 1.0 to be clinically significant, 18 subjects in each arm would be required to achieve a test of significance of 0.05 and a power of 0.8. Considering possible dropouts, we aim at recruiting 18 patients in each arm, i.e. 36 patients.

In order to compare one of the secondary outcome -- AMH (which has more relevance on the effect of ovarian response) with adequate power, based on our own database for patients undergoing IVF treatment, the mean AMH of the group with poor ovarian reserve is 0.8 with a SD of 0.6. Assuming an increase of number of oocyte retrieved by 0.5 to be clinically significant, 25 subjects in each arm would be required to achieve a test of significance of 0.01 and a power of 0.9. Totally 50 patients.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • Reproductive aging
  • DHEA
  • poor ovarian responder
04

Who can participate

Ages eligible
22 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age\<45 years,
  2. subfertility >1 year, and
  3. A previous POR (≤3 oocytes with a conventional stimulation protocol of at least 150 IU FSH per day); or
  4. An abnormal ovarian reserve test (i.e. AFC ≤5-7 follicles or AMH ≤0.5-1.1 ng/ml).

Exclusion criteria

Exclusion Criteria:

Patients were excluded if they:

  1. had a history of ovarian cystectomy or oophorectomy,
  2. had received cytotoxic chemotherapy,
  3. had received pelvic irradiation, or
  4. had a history of taking testosterone or DHEA supplementation
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    High dose group

    dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..

    Dietary Supplement: dehydroepiandrosterone

  • Other
    Standard dose group

    dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.

    Dietary Supplement: dehydroepiandrosterone

Interventions

  • Dietary supplementdehydroepiandrosterone

    high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.

    Also known as: DHEA (Lab Hercules™)

06

What researchers measure

Primary outcomes

  1. The Number of Oocytes Obtained

    After 12 weeks treatment, the number of oocytes obtained will be detected from the higher dose group and standard dose group

    Time frame: After taking DHEA for 12 weeks

Secondary outcomes

  1. AFC

    Antral follicle count (AFC)

    Time frame: After taking DHEA for 12 weeks

  2. Follicle Stimulating Hormone (FSH) Levels

    The change of FSH levels in the three groups.

    Time frame: 12 weeks after taking DHEA

  3. E2

    Serum E2 levels

    Time frame: 12 weeks after taking DHEA

  4. The Number of Follicles>10mm

    The number of follicles\>10mm represent for the ovarian reserve and response

    Time frame: 12 weeks after taking DHEA

  5. AMH

    The change of AMH levels in serum

    Time frame: baseline and 12 weeks

  6. Testosterone

    Time frame: 12 weeks after taking DHEA

  7. Dehydroepiandrosterone-Sulfide (DHEA-S)

    Time frame: 12 weeks after taking DHEA

  8. Insulin-like Growth Factor-1 (IGF-1)

    Time frame: 12 weeks after taking DHEA

Other outcomes

  1. The Number of Mature Oocytes Obtained

    Time frame: up to 12 weeks

  2. Pregnancy Rate

    The rate of clinical pregnancy

    Time frame: 2 weeks after transfer

  3. the Numbers of Fertilized Embryos

    Time frame: 12 weeks after taking DHEA

  4. the Numbers of Cleaved Embryos

    Time frame: After taking DHEA for 12 weeks

  5. the Numbers of Top-quality Embryos.

    top-quality embryos are represented for \>7cell on Day 3 and the fragments \<20%

    Time frame: 12 weeks after taking DHEA

07

Results

Posted Jun 24, 2025
Limitations and caveats
The primary outcome measure is oocyte obtained not the IVF clinical pregnancy and the early termination leading to small number of subjects analyzed.

Participant flow

Participant flow — Overall Study
MilestoneStandard Dose GroupHigh Dose Group
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryThe Number of Oocytes Obtained

After 12 weeks treatment, the number of oocytes obtained will be detected from the higher dose group and standard dose group

Time frame:
After taking DHEA for 12 weeks
Reported as:
Mean · oocytes
The Number of Oocytes Obtained
oocytesHigh Dose GroupStandard Dose Group
The Number of Oocytes Obtained3.82 ± 0.282.51 ± 0.22
Statistical analysis
  • High Dose Group vs Standard Dose Group · t-test, 2 sided · p = 0.0003 · Mean difference (final values): 1.31 · 95% CI 0.6216 to 2.002
SecondaryAFC

Antral follicle count (AFC)

Time frame:
After taking DHEA for 12 weeks
Reported as:
Mean · follicles
AFC
folliclesHigh Dose GroupStandard Dose Group
AFC4.00 ± 0.204.66 ± 0.26
SecondaryFollicle Stimulating Hormone (FSH) Levels

The change of FSH levels in the three groups.

Time frame:
12 weeks after taking DHEA
Reported as:
Mean · IU/L
Follicle Stimulating Hormone (FSH) Levels
IU/LHigh Dose GroupStandard Dose Group
Follicle Stimulating Hormone (FSH) Levels12.84 ± 0.9911.69 ± 0.83
SecondaryE2

Serum E2 levels

Time frame:
12 weeks after taking DHEA
Reported as:
Mean · pmol/L
E2
pmol/LHigh Dose GroupStandard Dose Group
E251.88 ± 5.6439.11 ± 4.44
SecondaryThe Number of Follicles>10mm

The number of follicles\>10mm represent for the ovarian reserve and response

Time frame:
12 weeks after taking DHEA
Reported as:
Mean · follicles
The Number of Follicles>10mm
folliclesHigh Dose GroupStandard Dose Group
The Number of Follicles>10mm8.24 ± 0.323.71 ± 0.24
SecondaryAMH

The change of AMH levels in serum

Time frame:
baseline and 12 weeks
Reported as:
Mean · ng/ml
AMH
ng/mlHigh Dose GroupStandard Dose Group
AMH3.05 ± 0.421.62 ± 0.15
SecondaryTestosterone
Time frame:
12 weeks after taking DHEA
Reported as:
Mean · ng/dl
Testosterone
ng/dlHigh Dose GroupStandard Dose Group
Testosterone31.67 ± 2.631.59 ± 1.94
SecondaryDehydroepiandrosterone-Sulfide (DHEA-S)
Time frame:
12 weeks after taking DHEA
Reported as:
Mean · ug/ml
Dehydroepiandrosterone-Sulfide (DHEA-S)
ug/mlHigh Dose GroupStandard Dose Group
Dehydroepiandrosterone-Sulfide (DHEA-S)2.69 ± 0.241.75 ± 0.20
SecondaryInsulin-like Growth Factor-1 (IGF-1)
Time frame:
12 weeks after taking DHEA
Reported as:
Mean · ng/ml
Insulin-like Growth Factor-1 (IGF-1)
ng/mlHigh Dose GroupStandard Dose Group
Insulin-like Growth Factor-1 (IGF-1)90.87 ± 6.5071.85 ± 4.39
Other pre-specifiedThe Number of Mature Oocytes Obtained
Time frame:
up to 12 weeks
Reported as:
Mean · oocytes
The Number of Mature Oocytes Obtained
oocytesHigh Dose GroupStandard Dose Group
The Number of Mature Oocytes Obtained4.1 ± 0.241.93 ± 0.27
Other pre-specifiedPregnancy Rate

The rate of clinical pregnancy

Time frame:
2 weeks after transfer
Reported as:
Number · percentage of pregnancy
Pregnancy Rate
percentage of pregnancyHigh Dose GroupStandard Dose Group
Pregnancy Rate74
Other pre-specifiedthe Numbers of Fertilized Embryos
Time frame:
12 weeks after taking DHEA
Reported as:
Mean · embryos
the Numbers of Fertilized Embryos
embryosHigh Dose GroupStandard Dose Group
the Numbers of Fertilized Embryos1.70 ± 0.171.92 ± 0.21
Other pre-specifiedthe Numbers of Cleaved Embryos
Time frame:
After taking DHEA for 12 weeks
Reported as:
Mean · embryos
the Numbers of Cleaved Embryos
embryosHigh Dose GroupStandard Dose Group
the Numbers of Cleaved Embryos1.63 ± 0.191.89 ± 0.23
Other pre-specifiedthe Numbers of Top-quality Embryos.

top-quality embryos are represented for \>7cell on Day 3 and the fragments \<20%

Time frame:
12 weeks after taking DHEA
Reported as:
Mean · embryos
the Numbers of Top-quality Embryos.
embryosHigh Dose GroupStandard Dose Group
the Numbers of Top-quality Embryos.1.11 ± 0.150.85 ± 0.13

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose Group—0/30 (0%)0/30 (0%)
Standard Dose Group—0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)High Dose GroupStandard Dose GroupTotal
<=18 years000
Between 18 and 65 years303060
>=65 years000
Age, Continuous
Age, Continuous(years)High Dose GroupStandard Dose GroupTotal
Mean38.40 ± 4.7037.68 ± 5.4038.3 ± 5.05
Sex: Female, Male
Sex: Female, Male(Participants)High Dose GroupStandard Dose GroupTotal
Female303060
Male000
08

Study locations

1 site
  • Ji Ai Genetics and IVF center
    Shanghai, Shanghai Municipality 200011, China
09

References and documents

Publications

  • Jenkins JM, Davies DW, Devonport H, Anthony FW, Gadd SC, Watson RH, Masson GM. Comparison of 'poor' responders with 'good' responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod. 1991 Aug;6(7):918-21. doi: 10.1093/oxfordjournals.humrep.a137459. PubMed 1761658 ↗
  • Ulug U, Ben-Shlomo I, Turan E, Erden HF, Akman MA, Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online. 2003 Jun;6(4):439-43. doi: 10.1016/s1472-6483(10)62164-5. PubMed 12831590 ↗
  • Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997 May;104(5):521-7. doi: 10.1111/j.1471-0528.1997.tb11525.x. No abstract available. PubMed 9166190 ↗
  • Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 Oct;15(10):2129-32. doi: 10.1093/humrep/15.10.2129. PubMed 11006185 ↗
  • Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005 Sep;84(3):756. doi: 10.1016/j.fertnstert.2005.02.049. PubMed 16169414 ↗
  • Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006 Nov;21(11):2845-9. doi: 10.1093/humrep/del254. Epub 2006 Sep 22. PubMed 16997936 ↗
  • Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007 Dec;24(12):629-34. doi: 10.1007/s10815-007-9178-x. Epub 2007 Dec 11. PubMed 18071895 ↗
  • Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol. 2009 Oct 7;7:108. doi: 10.1186/1477-7827-7-108. PubMed 19811650 ↗
  • Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial. Ann Rheum Dis. 2010 Jun;69(6):1144-7. doi: 10.1136/ard.2009.117036. Epub 2009 Oct 22. PubMed 19854713 ↗
  • Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G, Buster JE. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril. 1998 Jul;70(1):107-10. doi: 10.1016/s0015-0282(98)00121-6. PubMed 9660430 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Dec 2014, 11 months.

Results were first posted in Jun 2025, 10 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2015
First posted
Feb 6, 2015
StartActual
Jan 1, 2014
Primary completionActual
Dec 31, 2014
CompletionActual
Jan 1, 2015
Results first posted
Jun 24, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02357472
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Feb 6, 2015
Start date
Jan 1, 2014
Primary completion
Dec 31, 2014
Completion
Jan 1, 2015
Results posted
Jun 24, 2025
Last update
Jun 24, 2025

Study contacts

Xiao Xi Sun, PHD,MD
study chair · Shang Hai JIAi genetics & IVF center
Jing Fu, MD
principal investigator · Shang Hai JIAi genetics & IVF center
Ying Su Liu, PHD,MD
study director · Shang Hai JIAi Genetics & IVF center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dehydroepiandrosterone

Start the discussion